Insider Buy/Sell Details for the Biotechnology Industry — Last 30 Days
Ratio0.1:1
Daily Buy & Sell Volume
Transactions (1185)
REGENERON PHARMACEUTICALS, INC. (REGN)
RYAN ARTHUR F — Director
Shares
7
Price
$706.74
Total Value
$4.95K
Shares Held After
17,523
% of Holdings
0.0%
REGENERON PHARMACEUTICALS, INC. (REGN)
RYAN ARTHUR F — Director
Shares
14
Price
$705.56
Total Value
$9.88K
Shares Held After
17,530
% of Holdings
0.1%
REGENERON PHARMACEUTICALS, INC. (REGN)
RYAN ARTHUR F — Director
Shares
15
Price
$704.28
Total Value
$10.56K
Shares Held After
17,544
% of Holdings
0.1%
REGENERON PHARMACEUTICALS, INC. (REGN)
RYAN ARTHUR F — Director
Shares
24
Price
$703.46
Total Value
$16.88K
Shares Held After
17,559
% of Holdings
0.1%
REGENERON PHARMACEUTICALS, INC. (REGN)
RYAN ARTHUR F — Director
Shares
15
Price
$702.46
Total Value
$10.54K
Shares Held After
17,583
% of Holdings
0.1%
REGENERON PHARMACEUTICALS, INC. (REGN)
RYAN ARTHUR F — Director
Shares
5
Price
$701.76
Total Value
$3.51K
Shares Held After
17,598
% of Holdings
0.0%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
23
Price
$160.00
Total Value
$3.68K
Shares Held After
3,666
% of Holdings
0.6%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
38
Price
$159.08
Total Value
$6.04K
Shares Held After
3,689
% of Holdings
1.0%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
65
Price
$158.35
Total Value
$10.29K
Shares Held After
3,727
% of Holdings
1.7%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
106
Price
$157.45
Total Value
$16.69K
Shares Held After
3,792
% of Holdings
2.7%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
82
Price
$156.24
Total Value
$12.81K
Shares Held After
3,898
% of Holdings
2.1%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
346
Price
$155.48
Total Value
$53.79K
Shares Held After
3,980
% of Holdings
8.0%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
288
Price
$154.38
Total Value
$44.46K
Shares Held After
4,326
% of Holdings
6.2%
BELITE BIO, INC (BLTE)
MATA NATHAN L. — Chief Scientific Officer
Shares
52
Price
$153.89
Total Value
$8.00K
Shares Held After
4,614
% of Holdings
1.1%
CAPRICOR THERAPEUTICS, INC. (CAPR)
Krasney Karen — EVP, GENERAL COUNSEL
Shares
25,000
Price
$31.70
Total Value
$792.55K
Shares Held After
30,547
% of Holdings
45.0%
CAPRICOR THERAPEUTICS, INC. (CAPR)
Bergmann Anthony — CHIEF FINANCIAL OFFICER
Shares
25,000
Price
$31.70
Total Value
$792.54K
Shares Held After
8,223
% of Holdings
75.2%
Travere Therapeutics, Inc. (TVTX)
Baynes Roy D. — Director
Shares
9,750
Price
$44.22
Total Value
$431.14K
Shares Held After
37,500
% of Holdings
20.6%
CYTOKINETICS INC (CYTK)
Callos Andrew — EVP, Chief Commercial Officer
Shares
15,857
Price
$65.00
Total Value
$1.03M
Shares Held After
58,555
% of Holdings
21.3%
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Heshmatpour Amir F — Director
Shares
10,000
Price
$4.16
Total Value
$41.59K
Shares Held After
3,072,000
% of Holdings
0.3%
Vir Biotechnology, Inc. (VIR)
SATO VICKI L — Director
Shares
22,000
Price
$10.05
Total Value
$221.03K
Shares Held After
1,078,391
% of Holdings
2.0%
Spyre Therapeutics, Inc. (SYRE)
Burrows Scott L — Chief Financial Officer
Shares
12,500
Price
$71.37
Total Value
$892.12K
Shares Held After
97,994
% of Holdings
11.3%
Alkermes plc. (ALKS)
Hopkinson Craig C. — EVP R&D, Chief Medical Officer
Shares
9,000
Price
$33.40
Total Value
$300.56K
Shares Held After
81,389
% of Holdings
10.0%
Spyre Therapeutics, Inc. (SYRE)
Turtle Cameron — Director
Shares
300
Price
$74.96
Total Value
$22.49K
Shares Held After
612,540
% of Holdings
0.0%
Spyre Therapeutics, Inc. (SYRE)
Turtle Cameron — Director
Shares
1,700
Price
$74.23
Total Value
$126.19K
Shares Held After
612,840
% of Holdings
0.3%
Spyre Therapeutics, Inc. (SYRE)
Turtle Cameron — Director
Shares
3,100
Price
$73.14
Total Value
$226.73K
Shares Held After
614,540
% of Holdings
0.5%
Spyre Therapeutics, Inc. (SYRE)
Turtle Cameron — Director
Shares
1,000
Price
$71.76
Total Value
$71.76K
Shares Held After
617,640
% of Holdings
0.2%
Spyre Therapeutics, Inc. (SYRE)
Turtle Cameron — Director
Shares
3,600
Price
$70.77
Total Value
$254.77K
Shares Held After
618,640
% of Holdings
0.6%
Spyre Therapeutics, Inc. (SYRE)
Turtle Cameron — Director
Shares
5,300
Price
$69.54
Total Value
$368.56K
Shares Held After
622,240
% of Holdings
0.8%
Spyre Therapeutics, Inc. (SYRE)
Sloan Sheldon — Chief Medical Officer
Shares
400
Price
$75.37
Total Value
$30.15K
Shares Held After
0
% of Holdings
100.0%
Spyre Therapeutics, Inc. (SYRE)
Sloan Sheldon — Chief Medical Officer
Shares
5,059
Price
$74.60
Total Value
$377.40K
Shares Held After
400
% of Holdings
92.7%
Spyre Therapeutics, Inc. (SYRE)
Sloan Sheldon — Chief Medical Officer
Shares
10,358
Price
$73.74
Total Value
$763.80K
Shares Held After
5,459
% of Holdings
65.5%
Spyre Therapeutics, Inc. (SYRE)
Sloan Sheldon — Chief Medical Officer
Shares
12,777
Price
$72.94
Total Value
$931.95K
Shares Held After
15,817
% of Holdings
44.7%
Spyre Therapeutics, Inc. (SYRE)
Sloan Sheldon — Chief Medical Officer
Shares
8,777
Price
$71.56
Total Value
$628.08K
Shares Held After
28,594
% of Holdings
23.5%
Spyre Therapeutics, Inc. (SYRE)
Sloan Sheldon — Chief Medical Officer
Shares
19,656
Price
$70.61
Total Value
$1.39M
Shares Held After
37,371
% of Holdings
34.5%
Spyre Therapeutics, Inc. (SYRE)
Sloan Sheldon — Chief Medical Officer
Shares
21,306
Price
$69.53
Total Value
$1.48M
Shares Held After
57,027
% of Holdings
27.2%
Immunovant, Inc. (IMVT)
Susman Robert Graham — Director
Shares
2,502
Price
$27.17
Total Value
$67.98K
Shares Held After
36,394
% of Holdings
6.4%
Oruka Therapeutics, Inc. (ORKA)
Sandler Laura Lee — Chief Operating Officer
Shares
100
Price
$68.48
Total Value
$6.85K
Shares Held After
236,984
% of Holdings
0.0%
Oruka Therapeutics, Inc. (ORKA)
Sandler Laura Lee — Chief Operating Officer
Shares
200
Price
$67.16
Total Value
$13.43K
Shares Held After
237,084
% of Holdings
0.1%
Oruka Therapeutics, Inc. (ORKA)
Sandler Laura Lee — Chief Operating Officer
Shares
400
Price
$66.06
Total Value
$26.42K
Shares Held After
237,284
% of Holdings
0.2%
Oruka Therapeutics, Inc. (ORKA)
Sandler Laura Lee — Chief Operating Officer
Shares
300
Price
$65.10
Total Value
$19.53K
Shares Held After
237,684
% of Holdings
0.1%
Oruka Therapeutics, Inc. (ORKA)
Sandler Laura Lee — Chief Operating Officer
Shares
1,800
Price
$64.15
Total Value
$115.47K
Shares Held After
237,984
% of Holdings
0.8%
Oruka Therapeutics, Inc. (ORKA)
Sandler Laura Lee — Chief Operating Officer
Shares
2,200
Price
$62.58
Total Value
$137.69K
Shares Held After
239,784
% of Holdings
0.9%
Contineum Therapeutics, Inc. (CTNM)
Lorrain Daniel S. — Chief Scientific Officer
Shares
300
Price
$13.84
Total Value
$4.15K
Shares Held After
143,542
% of Holdings
0.2%
Contineum Therapeutics, Inc. (CTNM)
Lorrain Daniel S. — Chief Scientific Officer
Shares
3,870
Price
$13.06
Total Value
$50.54K
Shares Held After
143,842
% of Holdings
2.6%
Vaxcyte, Inc. (PCVX)
Wassil Jim — CHIEF OPERATING OFFICER
Shares
2,250
Price
$56.83
Total Value
$127.87K
Shares Held After
160,744
% of Holdings
1.4%
Xeris Biopharma Holdings, Inc. (XERS)
Hecht Beth — Chief Legal Officer and Corporate Secretary
Shares
16,667
Price
$6.23
Total Value
$103.81K
Shares Held After
1,193,173
% of Holdings
1.4%
Nurix Therapeutics, Inc. (NRIX)
Ring Christine — Chief Legal Officer
Shares
5,394
Price
$16.76
Total Value
$90.41K
Shares Held After
26,453
% of Holdings
16.9%
FENNEC PHARMACEUTICALS INC. (FENC)
Raykov Rosty — Director
Shares
10,781
Price
$6.47
Total Value
$69.75K
Shares Held After
121,451
% of Holdings
8.2%
Kiniksa Pharmaceuticals International, plc (KNSA)
Patel Sanj K — Director
Shares
48,565
Price
$54.02
Total Value
$2.62M
Shares Held After
0
% of Holdings
100.0%
Rein Therapeutics, Inc. (RNTX)
WINDSOR JAMES BRIAN — Director
Shares
25,000
Price
$1.00
Total Value
$25.00K
Shares Held After
27,046
% of Holdings
92.4%
Showing 651–700 of 1185 transactions (page 14 of 24)